Free Trial

Solid Biosciences (SLDB) Stock Price, News & Analysis

Solid Biosciences logo
$3.44 -0.26 (-7.03%)
Closing price 04:00 PM Eastern
Extended Trading
$3.43 -0.01 (-0.32%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Solid Biosciences Stock (NASDAQ:SLDB)

Key Stats

Today's Range
$3.43
$3.77
50-Day Range
$2.88
$6.47
52-Week Range
$2.88
$12.95
Volume
1.86 million shs
Average Volume
849,436 shs
Market Capitalization
$266.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.67
Consensus Rating
Buy

Company Overview

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Remove Ads

Solid Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

SLDB MarketRank™: 

Solid Biosciences scored higher than 68% of companies evaluated by MarketBeat, and ranked 335th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Solid Biosciences has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Solid Biosciences has only been the subject of 4 research reports in the past 90 days.

  • Read more about Solid Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Solid Biosciences are expected to grow in the coming year, from ($2.84) to ($2.63) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Solid Biosciences is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Solid Biosciences is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Solid Biosciences has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Solid Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    11.51% of the float of Solid Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Solid Biosciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Solid Biosciences has recently increased by 7.10%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Solid Biosciences does not currently pay a dividend.

  • Dividend Growth

    Solid Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.51% of the float of Solid Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Solid Biosciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Solid Biosciences has recently increased by 7.10%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Solid Biosciences has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Solid Biosciences this week, compared to 3 articles on an average week.
  • Search Interest

    Only 35 people have searched for SLDB on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.
  • MarketBeat Follows

    Only 32 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Solid Biosciences insiders have sold 109.86% more of their company's stock than they have bought. Specifically, they have bought $9,932.00 in company stock and sold $20,843.00 in company stock.

  • Percentage Held by Insiders

    13.63% of the stock of Solid Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Solid Biosciences' insider trading history.
Receive SLDB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SLDB Stock News Headlines

Truist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB)
Elon Tax Shock?
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
Solid Biosciences (SLDB) Receives a Buy from J.P. Morgan
Solid Biosciences (SLDB) Gets a Buy from Truist Financial
See More Headlines

SLDB Stock Analysis - Frequently Asked Questions

Solid Biosciences' stock was trading at $4.00 at the start of the year. Since then, SLDB stock has decreased by 14.0% and is now trading at $3.44.
View the best growth stocks for 2025 here
.

Solid Biosciences Inc. (NASDAQ:SLDB) announced its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by $0.12.

Shares of Solid Biosciences reverse split before market open on Friday, October 28th 2022. The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Solid Biosciences (SLDB) raised $130 million in an initial public offering on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Solid Biosciences investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
11/06/2024
Today
4/01/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLDB
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.67
High Stock Price Target
$20.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+355.4%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
12 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-96,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$8.09 million
Price / Cash Flow
N/A
Book Value
$6.27 per share
Price / Book
0.55

Miscellaneous

Free Float
35,048,000
Market Cap
$266.58 million
Optionable
Optionable
Beta
1.98
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:SLDB) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners